Chris Mirabile Net Worth Overview
Chris Mirabile is the founder of Novus Capital, a private investment platform focused on longevity science and early-stage technology. His estimated net worth reflects his roles as an entrepreneur, investor, and operator of venture-backed companies in the biotech and fintech sectors. Public estimates place his net worth in the multimillion-dollar range, driven by equity holdings, advisory roles, and capital deployed across his portfolio Forbes.
The primary sources of his wealth include ownership stakes in private companies, returns from venture investments, and advisory compensation from longevity-focused initiatives. His financial profile is closely tied to the growth of Novus Capital and its portfolio companies, which span healthtech, biotech, and digital assets. The valuation of his net worth fluctuates with private-market deals, fund performance, and market conditions in the longevity and technology sectors Forbes.
Career and Business Background
Mirabile founded Novus Capital to bridge longevity research with commercial applications, targeting companies developing therapies for age-related diseases. The platform curates deal flow, conducts due diligence, and supports startups with capital and strategic guidance. His career focuses on identifying high-impact science and translating it into investable ventures Forbes.
Before Novus Capital, he built experience in venture investing and corporate strategy, working with early-stage companies across health and technology. His professional background includes roles that combined scientific research with business development, positioning him to evaluate complex biotech and fintech opportunities. This trajectory shaped his current focus on longevity science as a core investment thesis Forbes.
Key Ventures and Investment Focus
Novus Capital and Longevity Investments
Novus Capital serves as the central vehicle for Mirabile's investments in longevity, targeting companies working on cellular repair, AI-driven drug discovery, and biomarkers of aging. The fund emphasizes early-stage opportunities with strong scientific foundations and clear paths to clinical or commercial validation. His net worth is closely linked to the performance of these ventures and their ability to secure follow-on funding and partnerships Forbes.
Beyond Novus Capital, Mirabile engages with a broader ecosystem of longevity startups and research initiatives, often acting as an advisor or angel investor. His portfolio includes companies exploring senolytics, epigenetic reprogramming, and precision medicine for age-related conditions. These activities contribute to his overall financial standing and reinforce his position in the longevity investment space Forbes.